Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Transplantation

• Publication date

  1994-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-199402000-00014PMID 8116041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations.

  1993cited by this paper
• Manipulating the immune system with immune globulin.

  1992cited by this paper
• Plasma exchange, splenectomy, and cyclophosphamide for natural antibody removal: kinetics and xenograft survival.

  1992cited by this paper
• Alloimmunization to platelet antigens.

  1992cited by this paper
• Treatment of systemic vasculitis with pooled intravenous immunoglobulin.

  1991cited by this paper
• A polyclonal model for B cell tolerance. I. Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig.

  1991cited by this paper
• Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin

  1991cited by this paper
• Anti‐idiotypes against anti‐neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis

  1991cited by this paper
• The use of intravenous immune globulin in immunodeficiency diseases.

  1991cited by this paper
• Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases

  1991cited by this paper
• IgG autoantibody activity in normal mouse serum is controlled by IgM.

  1990cited by this paper
• Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.

  1990cited by this paper
• A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients.

  1990cited by this paper
• Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins.

  1989cited by this paper
• Anti-idiotypic antibodies regulate the immune response to HLA in heart allograft recipients.

  1989cited by this paper
• ASSOCIATION OF ANTIIDIOTYPIC ANTIBODY WITH SUCCESSFUL SECOND TRANSPLANT OF A KIDNEY SHARING HLA ANTIGENS WITH THE PREVIOUS HYPERACUTELY REJECTED FIRST KIDNEY

  1989cited by this paper
• Two major serologic events in a successful cardiac transplant recipient--circumvention of hyperacute rejection despite a positive donor T lymphocyte crossmatch and late appearance of probable antiidiotypic antibody.

  1988cited by this paper
• Association between HLA phenotype and HLA concentration in plasma or platelets.

  1988cited by this paper
• Effect of antiidiotypic antibodies to HLA on graft survival in renal-allograft recipients.

  1987cited by this paper
• Evidence for immunosuppression by high-dose gammaglobulin.

  1987cited by this paper
• Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature.

  1987cited by this paper
• Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin.

  1984cited by this paper
• Histocompatibility in cardiac transplantation with particular reference to immunopathology of positive serologic crossmatch.

  1983cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

  1981cited by this paper

• A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients.

  2025cites this paper
• B-Cell Induction Therapies in Intestinal Transplantation.

  2024cites this paper
• Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms

  2023cites this paper
• BSHI and BTS UK guideline on the detection of alloantibodies in solid organ (and islet) transplantation

  2023cites this paper
• Antibody‐mediated rejection in xenotransplantation: Can it be prevented or reversed?

  2023cites this paper
• The first clinical pig heart transplant: Was IVIg or pig cytomegalovirus detrimental to the outcome?

  2022cites this paper
• Current Desensitization Strategies in Heart Transplantation

  2021cites this paper
• Challenges Surrounding Induction Protocols in Children

  2021cites this paper
• Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg

  2021cites this paper
• Monospecific and Polyreactive Monoclonal Antibodies against Human Leukocyte Antigen-E: Diagnostic and Therapeutic Relevance

  2021cites this paper
• Desensitization strategies: is it worth it?

  2020cites this paper
• BASICS OF HUMAN LEUKOCYTE ANTIGENS (HLA) SYSTEM AND ITS APPLICATION IN CLINICAL SPECIALTIES

  2020cites this paper
• Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation

  2020cites this paper
• Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.

  2019cites this paper
• Desensitization in HLA Incompatible Transplantation

  2019cites this paper
• Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.

  2019cites this paper
• HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs

  2017cites this paper
• Pediatric Renal Transplantation

  2017cites this paper
• Overview of Immunosuppressive Therapy in Solid Organ Transplantation.

  2017cites this paper
• Pancreatic Transplantation

  2017cites this paper
• Management of sensitized pediatric patients prior to renal transplantation

  2016cites this paper
• The clinical significance of HLA antibodies detected by solid phase assay In renal transplant recipients

  2016cites this paper
• The Current Status of Heart Transplantation

  2016cites this paper
• Intravenous immunoglobulin for antibody-mediated keratolimbal allograft rejection

  2015cites this paper
• Antibody-Mediated Rejection in Pediatric Kidney Transplantation: Pathophysiology, Diagnosis, and Management

  2015cites this paper
• Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity‐determining region peptide in the native sera

  2015cites this paper
• Translational research in kidney transplantation and the role of patient engagement

  2015cites this paper
• Modern approaches to incompatible kidney transplantation.

  2015cites this paper
• Intravenous immunoglobulin in kidney transplantation

  2015cites this paper
• Antibody-Mediated Rejection in Reconstructive Transplantation

  2015cites this paper
• Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results.

  2015cites this paper
• Equipoise: Ethical, Scientific, and Clinical Trial Design Considerations for Compatible Pair Participation in Kidney Exchange Programs

  2015influential citation
• Antibody-mediated rejection

  2015cites this paper
• Chapter 3 The Current Status of Heart Transplantation

  2015cites this paper
• Issues in solid-organ transplantation in children: translational research from bench to bedside

  2014cites this paper
• Desensitization for solid organ and hematopoietic stem cell transplantation

  2014cites this paper
• Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management

  2014cites this paper
• Heart Transplantation: New Realities, Challenges and Development- Demographics and Therapeutics

  2014cites this paper
• Kidney Transplantation in the Immunologically High-Risk Patient

  2014cites this paper
• Induction of PD-L1 on monocytes: a new mechanism by which IVIg inhibits mixed lymphocyte reactions.

  2014cites this paper
• Leffell Desensitization for solid organ and hematopoietic stem cell transplantation

  2014cites this paper
• Antibody-Mediated Rejection in Kidney Transplantation

  2014cites this paper
• Suppression of allo‐human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti‐HLA‐E IgG that mimics HLA‐I reactivities of IVIg

  2014cites this paper
• Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter Study

  2014cites this paper
• Investigations into the outcomes of HLA antibody incompatible renal transplantation and the influence of immune memory

  2014cites this paper
• Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation

  2014cites this paper
• Effect of a Proteasome Inhibitor Plus Steroids on HLA Antibodies in Sensitized Patients Awaiting a Renal Transplant

  2014cites this paper
• Basic Principles of Transplant Immunology

  2014cites this paper
• Challenges in pediatric renal transplantation.

  2014cites this paper
• Desensitization in kidney transplantation: review and future perspectives

  2014cites this paper
• Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles.

  2013cites this paper
• bone marrow engraftment in allosensitized recipients Preformed antibody, not primed T cells, is the initial and major barrier to

  2013cites this paper
• Antibody depletion for the treatment of crossmatch‐positive pediatric heart transplant recipients

  2013cites this paper
• Advances in antibody-mediated rejection

  2013cites this paper
• Desensitization for prevention of chronic antibody‐mediated rejection after kidney transplantation

  2013cites this paper
• Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?

  2013cites this paper
• A Case of Acute Antibody-Mediated Rejection Developed after Pretreatment with Rituximab and Plasma Exchange in a Highly-Sensitized Recipient with a Deceased Donor Kidney

  2012cites this paper
• Prevention of antibody‐mediated kidney transplant rejection

  2012cites this paper
• Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients.

  2012cites this paper
• Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis.

  2012cites this paper
• Transplant immunology for non-immunologist.

  2012cites this paper
• Management hochimmunisierter Nierentransplantatempfänger

  2012cites this paper
• Treatment options and strategies for antibody mediated rejection after renal transplantation.

  2012cites this paper
• Cardiac antibody–mediated rejection

  2012influential citation
• Red Blood Cell Transfusion Risks in Patients with End‐Stage Renal Disease

  2012cites this paper
• Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.

  2012cites this paper
• Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome.

  2012cites this paper
• The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review

  2012cites this paper
• The Role of the Crossmatch in Kidney Transplantation: Past, Present and Future.

  2012cites this paper
• HLA incompatible renal transplantation

  2012cites this paper
• Treatment update of sensitized pediatric kidney transplant recipients: a review.

  2012cites this paper
• Intravenous Immunoglobulin (IVIG) a Modulator of Immunity and Inflammation with Applications in Solid Organ Transplantation

  2012cites this paper
• The immune-modulator AS101 reduces anti-HLA antibodies in sera of sensitized patients: a structural approach.

  2012cites this paper
• Organ Transplant: Strategies for Prevention of Antibody-Mediated Allograft Rejection

  2011cites this paper
• Desensitization and crossmatch conversion in deceased donor kidney transplantation.

  2011cites this paper
• Current approaches to the management of highly sensitized kidney transplant patients.

  2011cites this paper
• Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients

  2011cites this paper
• Modifiers of complement activation for prevention of antibody-mediated injury to allografts

  2011cites this paper
• Desensitization in HLA-incompatible kidney recipients and survival.

  2011cites this paper
• Desensitization protocols and their outcome.

  2011cites this paper
• Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.

  2011cites this paper
• Living donor exchange programs: theory and practice.

  2011cites this paper
• The Altruistic Unbalanced Paired Kidney Exchange: Proof of Concept and Survey of Potential Donor and Recipient Attitudes

  2010influential citation
• Intracellular IFNgamma production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization.

  2010cites this paper
• Renal Transplantation Across HLA and ABO Antibody Barriers: Integrating Paired Donation into Desensitization Protocols

  2010cites this paper
• Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

  2010cites this paper
• Sensitized renal transplant recipients: current protocols and future directions

  2010cites this paper
• Bortezomib in Kidney Transplantation

  2010cites this paper
• Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction.

  2010cites this paper
• New approaches for desensitization strategies prior to kidney transplantation.

  2009cites this paper
• Organ Procurement and Transplantation Network/United Network for Organ Sharing Histocompatibility Committee Collaborative Study to Evaluate Prediction of Crossmatch Results in Highly Sensitized Patients

  2009cites this paper
• Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach.

  2009cites this paper
• Intravenous immunoglobulin as treatment for BK virus: Nephropathy

  2009cites this paper
• Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.

  2009cites this paper
• Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production

  2009cites this paper
• Living Donor Kidney Transplantation Across Positive Crossmatch: The University of Illinois at Chicago Experience

  2009cites this paper
• Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis

  2008cites this paper
• Histocompatibility in Renal Transplantation

  2008cites this paper
• Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy

  2008cites this paper
• High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.

  2008cites this paper